Avalo Therapeutics AVTX Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's other income (expense)?
- Avalo Therapeutics (AVTX) reported other income (expense) of $1.28M in Q1 2026.
- How has Avalo Therapeutics's other income (expense) changed year-over-year?
- Avalo Therapeutics's other income (expense) decreased by 16.0% year-over-year, from $1.53M to $1.28M.
- What is the long-term trend for Avalo Therapeutics's other income (expense)?
- Over 2 years (2021 to 2023), Avalo Therapeutics's other income (expense) has grown at a 31.7% compound annual growth rate (CAGR), from -$2.41M to -$4.18M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.